Agilon Health Charts Risky Turnaround After Steep Losses

Agilon Health Inc ((AGL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Agilon Health’s latest earnings call balanced a candid review of steep 2025 losses with a detailed turnaround blueprint for 2026. Management laid out quantified targets for revenue, medical margin and adjusted EBITDA, pointing to stronger analytics, clinical programs and cost cuts, but also underscored that elevated medical cost trends and regulatory uncertainty leave execution risk firmly in focus.

2026 Turnaround Targets Signal Path to Breakeven

Agilon guided 2026 revenue to $5.41 billion–$5.58 billion, down from $5.93 billion in 2025 as it exits unprofitable contracts. The company is targeting a medical margin swing from a $57 million loss in 2025 to $300 million–$350 million and adjusted EBITDA improving from a $296 million loss to roughly breakeven, with ACO REACH expected to add $20 million–$25 million.

Data-Driven Clinical Pathways and BOI Upgrades

Management highlighted scaled clinical pathways in heart failure, dementia and COPD, with congestive heart failure protocols now adopted by over 90% of the network. An upgraded burden‑of‑illness data pipeline covering more than 85% of members and AI‑based risk identification is expected to drive about a 40 basis‑point year‑over‑year lift in risk revenue, augmenting earlier coding changes.

Quality Outperformance Fuels Rising Incentive Upside

The platform’s composite quality score sits around 4.2 stars, ahead of benchmarks and supported by better care‑gap closure and primary‑care‑driven Star measure gains. On that foundation, Agilon expects to more than double its incentive contribution opportunity in 2026 versus 2025, offering a growing non‑premium earnings lever if performance holds.

Tighter Cost Controls and More Disciplined Growth

Agilon reported $35 million of operating cost reductions, exceeding earlier targets, and guided 2026 G&A to about $234 million with roughly $15 million in geo‑entry expense. The company has paused growth and exited structurally unprofitable contracts, including trimming Medicare Part D exposure to below 15% of membership, signalling a clear shift from scale toward economic sustainability.

ACO REACH Strength and Structural Tailwinds

The ACO REACH segment delivered $41 million of adjusted EBITDA in 2025 despite a weak fourth quarter, and is projected to remain a profit contributor in 2026. Management also views CMS’ new 10‑year LEAD model design as a structural positive for its government‑risk strategy and has extended its credit facility while planning a reverse stock split to support capital flexibility.

2025 Results Underscore Depth of the Hole

Financially, 2025 was described as unsatisfactory with fourth‑quarter revenue of $1.57 billion and full‑year revenue of $5.93 billion. Medical margin was negative $74 million in Q4 and negative $57 million for the year, while adjusted EBITDA losses reached $142 million in Q4 and $296 million for 2025 amid weaker risk revenue, market exits and unfavorable prior‑year development.

Rising Cost Trends and Large‑Claim Volatility

Medical cost trends ran hotter than expected, with 2025 trending about 6.5% and climbing to 7.2% in the third quarter and 7.4% used for fourth‑quarter reserves. For 2026 the company assumes a gross trend of 7.5% and net about 7.0%, while also pointing to several outsized 2025 inpatient claims and limited paid‑claim visibility as reasons for conservative reserving.

Membership Contraction as Profitability Takes Priority

Agilon finished 2025 with 511,000 members, including meaningful Medicare Advantage membership attrition of about 50,000 from disciplined recontracting and exits. For 2026 it expects roughly 430,000 Medicare Advantage members, including around 25,000 in care‑coordination‑fee arrangements, signalling management’s preference to sacrifice near‑term scale for better unit economics.

Policy Uncertainty and Risk‑Adjustment Headwinds

Management voiced concern over CMS’ advanced rate notice, citing potential for lower‑than‑expected 2027 rate increases and new normalization factors that cloud risk‑adjustment revenue. Particular worry centers on treatment of unlinked or audio‑only coding and broader risk‑model recalibration, leaving policy shifts as an external headwind to the turnaround thesis.

Limited Visibility Adds Execution Risk

The company acknowledged that quality measure runout and late‑quarter paid‑claims visibility remain incomplete and it did not fully recognize potential quality upside in guidance. That conservative stance, combined with noisy claims data, means the ambitious 2026 improvement targets depend heavily on execution and on how these uncertainties resolve through the year.

Guidance Frames Ambitious but Measured 2026 Recovery

For 2026 Agilon is targeting platform membership of 525,000–540,000, including about 430,000 Medicare Advantage and roughly 103,000 ACO members at the midpoint. Guidance embeds a 7.5% gross cost trend, around $625 million of incremental medical‑margin value from contracting and bids, reduced Part D exposure, G&A near $234 million, and at least $125 million in year‑end cash.

Agilon’s call painted a company in transition, absorbing the impact of 2025’s missteps while leaning into analytics, clinical programs and strict capital discipline to restore profitability. For investors, the story now hinges on whether management can navigate cost trends and regulatory uncertainty well enough to convert its detailed 2026 roadmap into a durable earnings recovery.